Globeflex Capital L P Makes New $1.09 Million Investment in Ironwood Pharmaceuticals, Inc. $IRWD

Globeflex Capital L P bought a new position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 259,809 shares of the biotechnology company’s stock, valued at approximately $1,094,000. Globeflex Capital L P owned 0.16% of Ironwood Pharmaceuticals at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the stock. Krilogy Financial LLC raised its holdings in shares of Ironwood Pharmaceuticals by 9.8% during the 1st quarter. Krilogy Financial LLC now owns 33,194 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 2,971 shares during the period. ProShare Advisors LLC boosted its holdings in Ironwood Pharmaceuticals by 9.6% in the 4th quarter. ProShare Advisors LLC now owns 36,315 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 3,170 shares during the period. Integrated Wealth Concepts LLC boosted its holdings in Ironwood Pharmaceuticals by 21.4% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 3,406 shares during the period. DGS Capital Management LLC grew its position in Ironwood Pharmaceuticals by 42.8% in the first quarter. DGS Capital Management LLC now owns 14,883 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 4,458 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV grew its position in Ironwood Pharmaceuticals by 7.8% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 76,951 shares of the biotechnology company’s stock valued at $259,000 after acquiring an additional 5,598 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Wall Street Zen raised shares of Ironwood Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Zacks Research lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. Finally, Weiss Ratings raised shares of Ironwood Pharmaceuticals from a “hold (c-)” rating to a “hold (c+)” rating in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $6.23.

Ironwood Pharmaceuticals Stock Performance

Shares of IRWD opened at $4.13 on Tuesday. Ironwood Pharmaceuticals, Inc. has a one year low of $1.01 and a one year high of $5.78. The stock has a 50-day moving average price of $4.09 and a 200 day moving average price of $3.90. The company has a market capitalization of $682.44 million, a P/E ratio of 5.36 and a beta of 0.20.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Thursday, August 6th. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The business had revenue of $113.04 million during the quarter, compared to analyst estimates of $114.84 million. Ironwood Pharmaceuticals had a net margin of 33.36% and a negative return on equity of 58.38%. As a group, equities research analysts forecast that Ironwood Pharmaceuticals, Inc. will post 1.04 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Julie Mchugh sold 21,571 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $3.73, for a total transaction of $80,459.83. Following the completion of the transaction, the director owned 250,749 shares in the company, valued at $935,293.77. The trade was a 7.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Ronald Silver sold 127,890 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $4.52, for a total value of $578,062.80. Following the transaction, the insider owned 313,680 shares of the company’s stock, valued at approximately $1,417,833.60. The trade was a 28.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 9.30% of the stock is currently owned by insiders.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial?stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.